RhumbLine Advisers’s Medicines Co MDCO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-260,584
Closed -$22.1M 2967
2019
Q4
$22.1M Buy
260,584
+22,098
+9% +$1.47M 0.04% 445
2019
Q3
$11.9M Buy
238,486
+16,903
+8% +$674K 0.02% 689
2019
Q2
$8.08M Buy
221,583
+25,855
+13% +$844K 0.02% 910
2019
Q1
$5.47M Buy
195,728
+107
+0.1% +$2.52K 0.01% 1124
2018
Q4
$3.74M Buy
195,621
+35,238
+22% +$820K 0.01% 1272
2018
Q3
$4.8M Sell
160,383
-2,758
-2% -$104K 0.01% 1135
2018
Q2
$5.99M Buy
163,141
+4,642
+3% +$151K 0.01% 982
2018
Q1
$5.22M Buy
158,499
+2,139
+1% +$66.8K 0.01% 1012
2017
Q4
$4.28M Buy
156,360
+14,090
+10% +$434K 0.01% 1171
2017
Q3
$5.27M Sell
142,270
-3,335
-2% -$123K 0.01% 997
2017
Q2
$5.53M Buy
145,605
+58
+0% +$2.58K 0.01% 949
2017
Q1
$7.12M Buy
145,547
+40,945
+39% +$1.87M 0.02% 811
2016
Q4
$3.55M Buy
104,602
+3,906
+4% +$139K 0.01% 1123
2016
Q3
$3.8M Buy
100,696
+5,323
+6% +$201K 0.01% 1041
2016
Q2
$3.21M Sell
95,373
-27,537
-22% -$971K 0.01% 1061
2016
Q1
$3.9M Buy
122,910
+10,790
+10% +$352K 0.01% 975
2015
Q4
$4.19M Buy
112,120
+5,080
+5% +$192K 0.01% 912
2015
Q3
$4.06M Buy
107,040
+4,060
+4% +$143K 0.01% 915
2015
Q2
$2.95M Buy
102,980
+18,065
+21% +$503K 0.01% 1156
2015
Q1
$2.38M Buy
84,915
+8,315
+11% +$234K 0.01% 1287
2014
Q4
$2.12M Sell
76,600
-2,415
-3% -$59.8K 0.01% 1321
2014
Q3
$1.76M Sell
79,015
-2,510
-3% -$63.7K 0.01% 1406
2014
Q2
$2.37M Buy
81,525
+691
+0.9% +$18.5K 0.01% 1258
2014
Q1
$2.3M Sell
80,834
-2,970
-4% -$98.3K 0.01% 1259
2013
Q4
$3.24M Buy
83,804
+4,330
+5% +$155K 0.01% 1063
2013
Q3
$2.66M Buy
79,474
+2,449
+3% +$78K 0.01% 1165
2013
Q2
$2.37M Buy
+77,025
New +$2.58M 0.01% 1194

Other funds holding MDCO

RhumbLine Advisers's MDCO Position: Q1 2020 in Review

RhumbLine Advisers sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 260,584 shares — an estimated $22.1M sold.

RhumbLine Advisers first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $22.1M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

  • RhumbLine Advisers reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 260,584 Medicines Co shares in Q1 2020, an estimated $22.1M.
  • RhumbLine Advisers first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
  • RhumbLine Advisers's Medicines Co position peaked at $22.1M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on RhumbLine Advisers's 13F filing for Q1 2020, filed 6 May 2020.